Top

Published in:

Open Access 01-12-2023 | Melanoma | Research

High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients

Authors: Yasaman Rezaie, Fahimeh Fattahi, Baharnaz Mashinchi, Kambiz Kamyab Hesari, Sahar Montazeri, Elham Kalantari, Zahra Madjd, Leili Saeednejad Zanjani

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Talin-1 as a component of multi-protein adhesion complexes plays a role in tumor formation and migration in various malignancies. This study investigated Talin-1 in protein levels as a potential prognosis biomarker in skin tumors.

Methods

Talin-1 was evaluated in 106 skin cancer (33 melanomas and 73 non-melanomas skin cancer (NMSC)) and 11 normal skin formalin-fixed paraffin-embedded (FFPE) tissue samples using immunohistochemical technique on tissue microarrays (TMAs). The association between the expression of Talin-1 and clinicopathological parameters, as well as survival outcomes, were assessed.

Results

Our findings from data minings through bioinformatics tools indicated dysregulation of Talin-1 in mRNA levels for skin cancer samples. In addition, there was a statistically significant difference in Talin-1 expression in terms of intensity of staining, percentage of positive tumor cells, and H-score in melanoma tissues compared to NMSC (P = 0.001, P < 0.001, and P < 0.001, respectively). Moreover, high cytoplasmic expression of Talin-1 was found to be associated with significantly advanced stages (P = 0.024), lymphovascular invasion (P = 0.023), and recurrence (P = 0.006) in melanoma cancer tissues. Our results on NMSC showed a statistically significant association between high intensity of staining and the poor differentiation (P = 0.044). No significant associations were observed between Talin-1 expression levels and survival outcomes of melanoma and NMSC patients.

Conclusion

Our observations showed that higher expression of Talin1 in protein level may be significantly associated with more aggressive tumor behavior and advanced disease in patients with skin cancer. However, further studies are required to find the mechanism of action of Talin-1 in skin cancers.

Available only for authorised users

Aggarwal P, Knabel P, Fleischer AB Jr. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol. 2021;85(2):388–95.PubMedCrossRef

Urban K, Mehrmal S, Uppal P, Giesey RL, Delost GR. The global burden of skin cancer: a longitudinal analysis from the global burden of Disease Study, 1990–2017. JAAD Int. 2021;2:98–108.PubMedPubMedCentralCrossRef

Lomas A, Leonardi-Bee J, Bath‐Hextall FJBJoD. A systematic review of worldwide incidence of nonmelanoma skin cancer. 2012;166(5):1069–80.

Ward WH, Farma JM. Cutaneous melanoma: etiology and therapy [Internet]. 2017.

Bolick NL, Geller AC. Epidemiology of melanoma. Hematology/Oncology Clin. 2021;35(1):57–72.CrossRef

Lai V, Cranwell W, Sinclair RJCid. Epidemiol skin cancer mature patient. 2018;36(2):167–76.

Siegel RL, Miller KD, Fuchs HE, Jemal AJCacjfc. Cancer statistics, 2022. 2022.

Aggarwal P, Knabel P, Fleischer Jr, ABJJotAAoD. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. 2021;85(2):388–95.

Urban K, Mehrmal S, Uppal P, Giesey RL, Delost GRJJi. The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990–2017. 2021;2:98–108.

10.

Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, et al. Why is melanoma so metastatic? Pigment cell & melanoma research. 2014;27(1):19–36.CrossRef

11.

[Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html.

12.

Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson JJCe. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe–a systematic review of the literature. 2016;8:109.

13.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.PubMedPubMedCentralCrossRef

14.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. 2015;386(9992):444–51.CrossRef

15.

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.PubMedCrossRef

16.

Weinstein D, Leininger J, Hamby C, Safai B. Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol. 2014;7(6):13–24.PubMedPubMedCentral

17.

Bridge JA, Lee JC, Daud A, Wells JW. Bluestone JAJFim. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. 2018;5:351.

18.

Pandey SN. Skin Cancer: molecular biomarker for diagnosis, prognosis, Prevention, and targeted therapy. Skin Cancer: Pathogenesis and Diagnosis: Springer; 2021. pp. 101–30.

19.

Tonella L, Pala V, Ponti R, Rubatto M, Gallo G, Mastorino L et al. Prognostic and predictive biomarkers in stage iii melanoma: Current insights and clinical implications. 2021;22(9):4561.

20.

Mårtenson ED, Hansson L, Nilsson B, Von Schoultz E, Brahme EM, Ringborg U et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. 2001;19(3):824–31.

21.

Nayal A, Webb DJ. Horwitz AFJCoicb. Talin: an emerging focal point of adhesion dynamics. 2004;16(1):94 – 8.

22.

Critchley DJBST. Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion. 2004;32(5):831–6.

23.

Haining AWM, Rahikainen R, Cortes E, Lachowski D, Rice A, von Essen M, et al. Mechanotransduction in talin through the interaction of the R8 domain with DLC1. PLoS Biol. 2018;16(7):e2005599.PubMedPubMedCentralCrossRef

24.

Zacharchenko T, Qian X, Goult BT, Jethwa D, Almeida TB, Ballestrem C, et al. LD motif recognition by talin: structure of the talin-DLC1 complex. Structure. 2016;24(7):1130–41.PubMedPubMedCentralCrossRef

25.

Sun Z, Tseng H-Y, Tan S, Senger F, Kurzawa L, Dedden D, et al. Kank2 activates talin, reduces force transduction across integrins and induces central adhesion formation. Nat Cell Biol. 2016;18(9):941–53.PubMedPubMedCentralCrossRef

26.

Chakraborty S, Banerjee S, Raina M, Haldar SJB. Force-directed “mechanointeractome. of Talin–Integrin. 2019;58(47):4677–95.

27.

Yao M, Goult BT, Klapholz B, Hu X, Toseland CP, Guo Y, et al. Mech response talin. 2016;7(1):1–11.

28.

Haining AW, Lieberthal TJ, Hernández AdRJTFJ. Talin: a mechanosensitive molecule in health and disease. 2016;30(6):2073–85.

29.

Critchley DR. Gingras ARJJocs. Talin at a glance. 2008;121(9):1345–7.

30.

Murrell M, Oakes PW, Lenz M, Gardel ML. Forcing cells into shape: the mechanics of actomyosin contractility. Nat Rev Mol Cell Biol. 2015;16(8):486–98.PubMedPubMedCentralCrossRef

31.

Nagano M, Hoshino D, Koshikawa N, Akizawa T, Seiki M. Turnover of focal adhesions and cancer cell migration. International journal of cell biology. 2012;2012.

32.

Kaiser HW, Ness W, Offers M, O’Keefe EJ. Kreysel HWJJoid. Talin: adherens junction protein is localized at the epidermal-dermal interface in skin. 1993;101(6):789 – 93.

33.

Hume AN, Collinson LM, Hopkins CR, Strom M, Barral DC, Bossi G, et al. The leaden gene product is required with Rab27a to recruit myosin va to melanosomes in melanocytes. Traffic. 2002;3(3):193–202.PubMedCrossRef

34.

Jevnikar Z, Rojnik M, Jamnik P, Doljak B, Fonović UP, Kos JJJoBC. Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells. 2013;288(4):2201–9.

35.

Lai MT, Hua CH, Tsai MH, Wan L, Lin YJ, Chen CM et al. Talin-1 overexpression defines high risk for aggressive oral squamous cell carcinoma and promotes cancer metastasis. 2011;224(3):367 – 76.

36.

Fang K-P, Zhang J-L, Ren Y-H, Qian Y-B. Talin-1 correlates with reduced invasion and migration in human hepatocellular carcinoma cells. Asian Pac J Cancer Prev. 2014;15(6):2655–61.PubMedCrossRef

37.

Yan H, Guo M, Zou J, Xiao F, Yi L, He Y, et al. Promotive effect of Talin-1 protein on gastric cancer progression through PTK2‐PXN‐VCL‐E‐Cadherin‐CAPN2‐MAPK1 signaling axis. J Clin Lab Anal. 2020;34(12):e23555.PubMedPubMedCentralCrossRef

38.

Xu Y-F, Ren X-Y, Li Y-Q, He Q-M, Tang X-R, Sun Y, et al. High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. BMC Cancer. 2015;15(1):1–10.CrossRef

39.

Vafaei S, Saeednejad Zanjani L, Habibi Shams Z, Naseri M, Fattahi F, Gheytanchi E, et al. Low expression of Talin1 is associated with advanced pathological features in colorectal cancer patients. Sci Rep. 2020;10(1):1–18.CrossRef

40.

Xu N, Chen H-J, Chen S-H, Xue X-Y, Chen H, Zheng Q-S et al. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer. 2016;95(29).

41.

Bostanci O, Kemik O, Kemik A, Battal M, Demir U, Purisa S, et al. A novel screening test for colon cancer. Talin-1. 2014;18(17):2533–7.

42.

Xu Y-F, Ren X-Y, Li Y-Q, He Q-M, Tang X-R, Sun Y et al. High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. 2015;15(1):1–10.

43.

Ji L, Jiang F, Cui X. Qin CJOl. Talin1 knockdown prohibits the proliferation and migration of colorectal cancer cells via the EMT signaling pathway Retraction in/10.3892/ol. 2021.12943. 2019;18(5):5408-16.

44.

Sakamoto S, McCann RO, Dhir R. Kyprianou NJCr. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. 2010;70(5):1885-95.

45.

Duraiyan J, Govindarajan R, Kaliyappan K. Palanisamy MJJop, sciences b. Appl Immunohistochem. 2012;4(Suppl 2):307.

46.

Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W60.PubMedPubMedCentralCrossRef

47.

Park S-J, Yoon B-H, Kim S-K, Kim S-Y. GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genom. 2019;12(5):101.CrossRef

48.

Goldman M, Craft B, Hastie M, Repečka K, Kamath A, McDade F et al. The UCSC Xena platform for public and private cancer genomics data visualization and interpretation.bioRxiv. 2019:326470.

49.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL. Balch. AJCC Cancer Staging Manual (8th edition): Springer International Publishing: American Joint Commission on Cancer; 2017

50.

Kallioniemi O-P, Wagner U, Kononen J, Sauter GJHmg. Tissue microarray technology for high-throughput molecular profiling of cancer. 2001;10(7):657–62.

51.

Fedor HL, Marzo AMDJPC. Practical methods for tissue microarray construction. 2005:89–101.

52.

Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KRJAjopm. Prevalence and costs of skin cancer treatment in the US, 2002 – 2006 and 2007 – 2011. 2015;48(2):183–7.

53.

Kuphal S, Bauer R, Bosserhoff A-K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005;24(2):195–222.PubMedCrossRef

54.

Zhao Y, Lykov N, Tzeng CJIJoMM. Talin–1 interaction network in cellular mechanotransduction. 2022;49(5):1–12.

55.

Helige C, Hofmann-Wellenhof R, Fink-Puches R, Smolle J. Mofarotene-induced inhibition of melanoma cell motility by increasing vinculin-containing focal contacts. Melanoma Res. 2004;14(6):547–54.PubMedCrossRef

56.

Toma-Jonik A, Widlak W, Korfanty J, Cichon T, Smolarczyk R, Gogler-Piglowska A, et al. Active heat shock transcription factor 1 supports migration of the melanoma cells via vinculin down-regulation. Cell Signal. 2015;27(2):394–401.PubMedCrossRef

57.

Nelson ES, Folkmann AW, Henry MD, DeMali KA. Vinculin activators target integrins from within the cell to increase melanoma sensitivity to chemotherapy. Mol Cancer Res. 2011;9(6):712–23.PubMedPubMedCentralCrossRef

58.

Sadano H, Inoue M, Taniguchi S. Differential expression of vinculin between weakly and highly metastatic B16-melanoma cell lines. Jpn J Cancer Res. 1992;83(6):625–30.PubMedPubMedCentralCrossRef

59.

Brézillon S, Radwanska A, Zeltz C, Malkowski A, Ploton D, Bobichon H, et al. Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes. Cancer Lett. 2009;283(1):92–100.PubMedCrossRef

60.

Das M, Ithychanda SS, Qin J, Plow EFJBEBA-B. Mech talin-dependent integrin Signal crosstalk. 2014;1838(2):579–88.

61.

Katoh KJC. FAK-dependent cell motility and cell elongation. 2020;9(1):192.

62.

Chamcheu JC, Roy T, Uddin MB, Banang-Mbeumi S, Chamcheu R-CN, Walker AL et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. 2019;8(8):803.

63.

Davies MAJTCJ. The role of the PI3K-AKT pathway in melanoma. 2012;18(2):142–7.

64.

Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, et al. AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis. Mol Cancer Res. 2019;17(9):1787–800.PubMedPubMedCentralCrossRef

65.

Akasaka T, van Leeuwen RL, Yoshinaga IG, Mihm MC Jr, Byers HR. Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines. J Invest dermatology. 1995;105(1):104–8.CrossRef

66.

Kahana O, Micksche M, Witz IP, Yron I. The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. Oncogene. 2002;21(25):3969–77.PubMedCrossRef

67.

Hess AR, Postovit L-M, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, et al. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res. 2005;65(21):9851–60.PubMedCrossRef

68.

Hodorogea A, Calinescu A, Antohe M, Balaban M, Nedelcu RI, Turcu G et al.Epithelial-mesenchymal transition in skin cancers: a review. 2019;2019.

69.

Kuphal S, Martyn AC, Pedley J, Crowther LM, Bonazzi VF, Parsons PG, et al. H-cadherin expression reduces invasion of malignant melanoma. 2009;22(3):296–306.

70.

Bauer R, Hein R, Bosserhoff, AKJEcr. A secreted form of P-cadherin is expressed in malignant melanoma. 2005;305(2):418–26.

71.

Bécam IE, Tanentzapf G, Lepesant J-A, Brown NH, Huynh J-RJNcb. Integrin-independent repression of cadherin transcription by talin during axis formation in Drosophila. 2005;7(5):510–6.

72.

Krajewski A, Gagat M, Mikołajczyk K, Izdebska M, Żuryń A, Grzanka AJCM et al. Cyclin F downregulation affects epithelial-mesenchymal transition increasing proliferation and migration of the A-375 melanoma cell line. 2020;12:13085.

73.

Thapa N, Tan X, Choi S, Wise T, Anderson RJO. PIPKIγ and talin couple phosphoinositide and adhesion signaling to control the epithelial to mesenchymal transition. 2017;36(7):899–911.

74.

Vafaei S, Saeednejad Zanjani L, Habibi Shams Z, Naseri M, Fattahi F, Gheytanchi E et al. Low expression of Talin1 is associated with advanced pathological features in colorectal cancer patients. 2020;10(1):1–18.

75.

Azizi L, Cowell AR, Mykuliak VV, Goult BT, Turkki P, Hytönen VP. Cancer associated talin point mutations disorganise cell adhesion and migration. Sci Rep. 2021;11(1):1–16.CrossRef

76.

Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski PJIJoMS. Target therapy melanoma Mech Resist. 2020;21(13):4576.

77.

Liu-Smith F, Jia J. Zheng YJUlihh, diseases, environment. UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer. 2017:27–40.

78.

Xu X, Chen L, Guerry D, Dawson PR, Hwang W-t, VanBelle P et al. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. 2012;18(1):229–37.

79.

Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, et al. Talin binding to integrin ß tails: a final common step in integrin activation. Science. 2003;302(5642):103–6.PubMedCrossRef

80.

Lagarrigue F, Paul DS, Gingras AR, Valadez AJ, Sun H, Lin J, et al. Talin-1 is the principal platelet Rap1 effector of integrin activation. Blood. 2020;136(10):1180–90.PubMedPubMedCentralCrossRef

81.

Nieswandt B, Varga-Szabo D, Elvers M. Integrins in platelet activation. J Thromb Haemost. 2009;7:206–9.PubMedCrossRef

82.

Yan H, Guo M, Zou J, Xiao F, Yi L, He Y et al. Promotive effect of Talin-1 protein on gastric cancer progression through PTK2‐PXN‐VCL‐E‐Cadherin‐CAPN2‐MAPK1 signaling axis. 2020;34(12):e23555.

83.

Apalla Z, Lallas A, Sotiriou E, Lazaridou E. Ioannides DJDp, conceptual. Epidemiol trends skin cancer. 2017;7(2):1.

84.

Weinberg AS, Ogle CA, Shim EKJDs. Metastatic cutaneous squamous cell carcinoma: an update. 2007;33(8):885–99.

85.

Rahimi-Nedjat RK, Tuettenberg A, Sagheb K, Loquai C, Rybczynski B, Grabbe S et al. Factors accelerating recurrences and secondary tumors in cutaneous squamous cell carcinoma. 2021;49(4):317–22.

86.

Hardisson DJEAoO-R-L. Molecular pathogenesis of head and neck squamous cell carcinoma. 2003;260(9):502–8.

87.

Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JTJTJoci. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. 2012;122(2):464–72.

88.

89.

Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J translational Med. 2012;10:1–9.CrossRef

90.

Marquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, Gonzalez-Cao M et al.Immune checkpoint inhibitors: therapeutic advances in melanoma. 2015;3(18).

91.

Furue M, Ito T, Wada N, Wada M, Kadono T. Uchi HJCor. Melanoma and immune checkpoint inhibitors. 2018;20(3):1–8.

92.

Carlino MS, Larkin J, Long GVJTL. Immune Checkp inhibitors melanoma. 2021;398(10304):1002–14.

93.

Kozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: how melanoma cells evade targeted therapies. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2019;1871(2):313–22.CrossRef

94.

Orgaz JL, Crosas-Molist E, Sadok A, Perdrix-Rosell A, Maiques O, Rodriguez-Hernandez I et al. Myosin II reactivation and cytoskeletal remodeling as a hallmark and a vulnerability in melanoma therapy resistance. 2020;37(1):85–103. e9.

95.

Barreno A, Orgaz JLJC. Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma. 2022;11(3):518.

96.

Misek S, Appleton K, Dexheimer T, Lisabeth E, Lo R, Larsen S, et al. Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells. Oncogene. 2020;39(7):1466–83.PubMedCrossRef

97.

Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, et al. Vemurafenib Resistance signature by Proteome Analysis offers New Strategies and Rational Therapeutic ConceptsVemurafenib Resistance signature in Melanoma. Mol Cancer Ther. 2015;14(3):757–68.PubMedCrossRef

98.

Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, et al. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 2016;35(5):462–78.PubMedCrossRef

99.

Orgaz JL, Crosas-Molist E, Sadok A, Perdrix-Rosell A, Maiques O, Rodriguez-Hernandez I, et al. Myosin II reactivation and cytoskeletal remodeling as a hallmark and a vulnerability in melanoma therapy resistance. Cancer Cell. 2020;37(1):85–103. e9.PubMedPubMedCentralCrossRef

100.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–7.PubMedPubMedCentralCrossRef

101.

Barreno A, Orgaz JL. Cytoskeletal remodelling as an Achilles’ heel for Therapy Resistance in Melanoma. Cells. 2022;11(3):518.PubMedPubMedCentralCrossRef

102.

Zhao Y, Lykov N, Tzeng C. Talin–1 interaction network in cellular mechanotransduction. Int J Mol Med. 2022;49(5):1–12.CrossRef

103.

Elosegui-Artola A, Oria R, Chen Y, Kosmalska A, Pérez-González C, Castro N, et al. Mechanical regulation of a molecular clutch defines force transmission and transduction in response to matrix rigidity. Nat Cell Biol. 2016;18(5):540–8.PubMedCrossRef

104.

Sjoestroem C, Khosravi S, Cheng Y, Safaee Ardekani G, Martinka M, Li G. DLC1 expression is reduced in human cutaneous melanoma and correlates with patient survival. Mod Pathol. 2014;27(9):1203–11.PubMedCrossRef

105.

Vlachostergios PJJAjotr. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors. 2021;13(11):12386.

Title: High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients
Authors: Yasaman Rezaie
Fahimeh Fattahi
Baharnaz Mashinchi
Kambiz Kamyab Hesari
Sahar Montazeri
Elham Kalantari
Zahra Madjd
Leili Saeednejad Zanjani
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Melanoma
Melanoma
Skin Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10771-z

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Test, evidence, transition projects in Scotland: developing the evidence needed for transition of effective interventions in cancer care from innovation into mainstream practice

A deep-learning approach for segmentation of liver tumors in magnetic resonance imaging using UNet++

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

Expression and regulatory network of E3 ubiquitin ligase NEDD4 family in cancers

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020